IP Practice: Sidley Austin

Law360, New York (August 18, 2008, 12:00 AM EDT) -- The number of Hatch-Waxman Act-related lawsuits will likely drop over the next five years, but generic companies may start to challenge biotechnology patents, said the co-head of Sidley Austin's intellectual property practice group.

David Pritikin, who is a partner in Sidley Austin's Chicago office, predicted that the number of Hatch-Waxman cases will fall precipitously. “A lot of cases have already been brought and litigated,” he said. Meanwhile, the number of new drugs coming onto the market has ebbed over the past few years.

At the same...
To view the full article, register now.